BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 16447725)

  • 1. [Development of personalized peptide vaccines for advanced cancer patients].
    Yamada A
    Rinsho Ketsueki; 2005 Jun; 46(6):433-8. PubMed ID: 16447725
    [No Abstract]   [Full Text] [Related]  

  • 2. [Peptide-based vaccine therapy for cancer patients].
    Yamada A
    Nihon Rinsho; 2005 Apr; 63 Suppl 4():602-7. PubMed ID: 15861717
    [No Abstract]   [Full Text] [Related]  

  • 3. [New era of tumor immunotherapy].
    Yoshitake Y; Nakatsura T; Nishimura Y
    Nihon Rinsho; 2005 Apr; 63 Suppl 4():46-55. PubMed ID: 15861634
    [No Abstract]   [Full Text] [Related]  

  • 4. Challenges for cancer vaccine development.
    Tabi Z; Man S
    Adv Drug Deliv Rev; 2006 Oct; 58(8):902-15. PubMed ID: 16979786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer vaccines for established cancer: how to make them better?
    Andrews DM; Maraskovsky E; Smyth MJ
    Immunol Rev; 2008 Apr; 222():242-55. PubMed ID: 18364006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multipeptide vaccination in cancer patients.
    Pilla L; Rivoltini L; Patuzzo R; Marrari A; Valdagni R; Parmiani G
    Expert Opin Biol Ther; 2009 Aug; 9(8):1043-55. PubMed ID: 19591629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. International conference: progress in vaccination against cancer-2006 (PIVAC 6), Granada, Spain.
    Aptsiauri N; Cabrera T; Pawelec G; Gouttefangeas C; Derhovanessian E; Garrido F; Garcia-Lora A
    Cancer Immunol Immunother; 2007 Aug; 56(8):1311-22. PubMed ID: 17375297
    [No Abstract]   [Full Text] [Related]  

  • 8. Immunotherapeutic peptide vaccination with leukemia-associated antigens.
    Rusakiewicz S; Molldrem JJ
    Curr Opin Immunol; 2006 Oct; 18(5):599-604. PubMed ID: 16870418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunological evaluation of neoadjuvant peptide vaccination before radical prostatectomy for patients with localized prostate cancer.
    Noguchi M; Yao A; Harada M; Nakashima O; Komohara Y; Yamada S; Itoh K; Matsuoka K
    Prostate; 2007 Jun; 67(9):933-42. PubMed ID: 17440952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccines: an innovative approach to treating cancer.
    Pazdur MP; Jones JL
    J Infus Nurs; 2007; 30(3):173-8. PubMed ID: 17505219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in the development of a therapeutic cancer vaccine.
    Avigan D
    J Natl Compr Canc Netw; 2005 Nov; 3 Suppl 1():S2-6. PubMed ID: 16280106
    [No Abstract]   [Full Text] [Related]  

  • 12. Tumor antigens as surrogate markers and targets for therapy and vaccines.
    Dalgleish A; Pandha H
    Adv Cancer Res; 2007; 96():175-90. PubMed ID: 17161680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Peptide vaccination therapy for malignant glioma].
    Yamanaka R; Itoh K
    Brain Nerve; 2007 Mar; 59(3):251-61. PubMed ID: 17370651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update on vaccines for solid tumors.
    Gajewski TF
    Clin Adv Hematol Oncol; 2004 Mar; 2(3):158-9. PubMed ID: 16166944
    [No Abstract]   [Full Text] [Related]  

  • 15. Personalized peptide vaccination: a new approach for advanced cancer as therapeutic cancer vaccine.
    Noguchi M; Sasada T; Itoh K
    Cancer Immunol Immunother; 2013 May; 62(5):919-29. PubMed ID: 23197273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunity to melanoma antigens: from self-tolerance to immunotherapy.
    Slingluff CL; Chianese-Bullock KA; Bullock TN; Grosh WW; Mullins DW; Nichols L; Olson W; Petroni G; Smolkin M; Engelhard VH
    Adv Immunol; 2006; 90():243-95. PubMed ID: 16730266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I clinical study with multiple peptide vaccines in combination with tetanus toxoid and GM-CSF in advanced-stage HLA-A*0201-positive melanoma patients.
    Bins A; Mallo H; Sein J; van den Bogaard C; Nooijen W; Vyth-Dreese F; Nuijen B; de Gast GC; Haanen JB
    J Immunother; 2007; 30(2):234-9. PubMed ID: 17471170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Current status and future perspective of peptide vaccine for biliary tract cancer].
    Aruga A
    Nihon Rinsho; 2015 Mar; 73 Suppl 3():823-6. PubMed ID: 25857143
    [No Abstract]   [Full Text] [Related]  

  • 19. A multipeptide vaccine is safe and elicits T-cell responses in participants with advanced stage ovarian cancer.
    Chianese-Bullock KA; Irvin WP; Petroni GR; Murphy C; Smolkin M; Olson WC; Coleman E; Boerner SA; Nail CJ; Neese PY; Yuan A; Hogan KT; Slingluff CL
    J Immunother; 2008 May; 31(4):420-30. PubMed ID: 18391753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunology and breast cancer: therapeutic cancer vaccines.
    Curigliano G; Rescigno M; Goldhirsch A
    Breast; 2007 Dec; 16 Suppl 2():S20-6. PubMed ID: 17706425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.